Advertisement Recently, HRSA publicly announced the issuance of a final rule clarifying when 340B covered entities can purchase and distribute orphan drugs through the 340B Drug Pricing Program. Separately, HRSA quietly posted a report on its completed audits of 340B covered entities through July 12, 2013. While the new rule does shed light on when 340B entities can purchase … Continue reading Health Resources and Services Administration (HRSA) Clarifies 340B Orphan Drug Exception But 340B Audit Enforcement Remains Murky